Functional polymorphisms of interleukin 4 and interleukin 10 may predict evolution and functional outcome of an ischaemic stroke

European Journal of Neurology

Volumn 18, Issue 4, 2011, Pages 637-643

  Marousi, S G ^a   Ellul, J ^a   Antonacopoulou, A ^a   Gogos, C ^a   Papathanasopoulos, P ^a   Karakantza, M ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Evolution; Interleukin 10; Interleukin 4; Ischaemic stroke; Outcome; Polymorphisms

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 4;

ADULT; AGED; ARTICLE; BARTHEL INDEX; BRAIN ISCHEMIA; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; GENE FREQUENCY; GENETIC RISK; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RATING SCALE; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCANDINAVIAN STROKE SCALE; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; BRAIN ISCHEMIA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-4; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOVERY OF FUNCTION; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STROKE;

EID: 79952725185     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03228.x     Document Type: Article

References (26)

1. Rodriguez-Yanez M, Castillo J. Role of inflammatory markers in brain ischemia. Curr Opin Neurol 2008; 21: 353-357.
2. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 1876-1890.
3. Pinto A, Tuttolomondo A, Casuccio A, et al. Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation (NVAF). Clin Sci (Lond) 2009; 116: 781-789.
4. Stoll G, Jander S, Schroeter M. Detrimental and beneficial effects of injury-induced inflammation and cytokine expression in the nervous system. Adv Exp Med Biol 2002; 513: 87-113.
5. Lappin MB, Campbell JD. The Th1-Th2 classification of cellular immune responses: concepts, current thinking and applications in haematological malignancy. Blood Rev 2000; 14: 228-239.
6. van Exel E, Gussekloo J, de Craen AJ, Bootsma-van der Wiel A, Frolich M, Westendorp RG. Inflammation and stroke: the Leiden 85-Plus Study. Stroke 2002; 33: 1135-1138.
7. Vila N, Castillo J, Davalos A, Esteve A, Planas AM, Chamorro A. Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke 2003; 34: 671-675.
8. Rosenwasser LJ, Klemm DJ, Dresback JK, et al. Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Clin Exp Allergy 1995; 25(Suppl. 2): 74-78.
9. Rees LE, Wood NA, Gillespie KM, Lai KN, Gaston K, Mathieson PW. The interleukin-10-1082 G/A polymorphism: allele frequency in different populations and functional significance. Cell Mol Life Sci 2002; 59: 560-569.
10. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24: 1-8.
11. Mormann M, Rieth H, Hua TD, et al. Mosaics of gene variations in the interleukin-10 gene promoter affect interleukin-10 production depending on the stimulation used. Genes Immun 2004; 5: 246-255.
12. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41.
13. Birschel P, Ellul J, Barer D. Progressing stroke: towards an internationally agreed definition. Cerebrovasc Dis 2004; 17: 242-252.
14. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J 1965; 14: 61-65.
15. Germer S, Higuchi R. Single-tube genotyping without oligonucleotide probes. Genome Res 1999; 9: 72-78.
16. Young JL, Libby P, Schonbeck U. Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost 2002; 88: 554-567.
17. Tan KT, Lip GY, Blann AD. Post-stroke inflammatory response: effects of stroke evolution and outcome. Curr Atheroscler Rep 2003; 5: 245-251.
18. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993; 178: 1041-1048.
19. Briscoe DM, Cotran RS, Pober JS. Effects of tumor necrosis factor, lipopolysaccharide, and IL-4 on the expression of vascular cell adhesion molecule-1 in vivo. Correlation with CD3+ T cell infiltration. J Immunol 1992; 149: 2954-2960.
20. Zee RY, Cook NR, Cheng S, et al. Polymorphism in the P-selectin and interleukin-4 genes as determinants of stroke: a population-based, prospective genetic analysis. Hum Mol Genet 2004; 13: 389-396.
21. Wang X, Cheng S, Brophy VH, et al. A meta-analysis of candidate gene polymorphisms and ischemic stroke in 6 study populations: association of lymphotoxin-alpha in nonhypertensive patients. Stroke 2009; 40: 683-695.
22. Trompet S, Pons D, DEC AJ, et al. Genetic variation in the interleukin-10 gene promoter and risk of coronary and cerebrovascular events: the PROSPER study. Ann N Y Acad Sci 2007; 1100: 189-198.
23. Klein W, Tromm A, Griga T, et al. Interleukin-4 and interleukin-4 receptor gene polymorphisms in inflammatory bowel diseases. Genes Immun 2001; 2: 287-289.
24. Castillo J, Leira R. Predictors of deteriorating cerebral infarct: role of inflammatory mechanisms. Would its early treatment be useful? Cerebrovasc Dis 2001; 11(Suppl. 1): 40-48.
25. Hegele RA, Dichgans M. Update on the genetics of stroke and cerebrovascular disease 2007. Stroke 2008; 39: 252-254.
26. Whitley E, Ball J. Statistics review 4: sample size calculations. Crit Care 2002; 6: 335-341.